NEWS & MEDIA
Hemogenyx Pharmaceuticals Plc – Welcomes N.Y. Lt. Governor to its Labs11 January 2018
Advanced biotech startup touts ground-breaking medical research, deep ties to New York State.
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, welcomed New York Lieutenant Governor Kathy Hochul to its labs at the SUNY Downstate Medical Center Biotech Incubator.
In addition to showing Hochul its cutting-edge facilities, Hemogenyx also briefed the Lieutenant Governor on its advanced technologies-and their potential to save lives.
“As a biotech company with its roots in New York, we were honored to welcome Lieutenant Governor Hochul to our labs,” said Dr. Vladislav Sandler, CEO of Hemogenyx. Hemogenyx, which went public last year on the London Stock Exchange, opened its first lab in Buffalo after winning the New York-state funded 43North business competition. Now its four scientists work out of two state-of-the-art labs inside SUNY Downstate Medical Center’s Biotech Incubator. “Having access to the high-quality facilities at SUNY Downstate has been instrumental to our success in creating a safer and more effective approach to bone marrow transplants,” added Dr. Sandler.
“By providing biotech businesses with state-of-the-art laboratory space and financial support in the early stages, the SUNY Downstate Biotech Incubator is setting them up with the tools they need to grow into our next entrepreneurial success stories,”said Lieutenant Governor Hochul. “Hemogenyx Pharmaceuticals is one such success story, launching their business in New York State with the 43 North Startup competition and continuing to expand at SUNY Downstate’s world-class facilities.”
Hochul’s visit to Hemogenyx was part of a larger tour of the SUNY Downstate Biotech Incubator. After seeing the facility, the Lieutenant Governor gave a special presentation of Governor Cuomo’s State of the State address.
|Hemogenyx Pharmaceuticals Limited||www.hemogenyx.com|
|Dr Vladislav Sandler, Chief Executive Officer & Co-Founder||Via Walbrook PR|
|Dr Robin Campbell, Chairman|
|Optiva Securities Ltd||Tel: +44 (0)20 3137 1902|
|Shard Capital Partners LLP||Tel: +44 (0)20 7186 9950|
|Damon Heath, Erik Woolgar|
|Peterhouse Corporate Finance Limited||Tel: +44 (0)20 7469 0930|
|Lucy Williams/Duncan Vasey|
|Walbrook PR (UK Media & Investor Relations)||Tel: +44 (0)20 7933 8780 or email@example.com|
|Paul McManus||Mob: +44 (0)7980 541 893|
|US Media enquiries|
|Lowell Goodman||Tel: +1 (323) 646-3249 or firstname.lastname@example.org|
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx’s two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.
For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange